Pharmacological reactivation of mutant p53: from protein structure to the cancer patient (Q30389604)

21 June 2017

1 reference

title

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient (English)

1 reference

21 June 2017

1 reference

1 reference

K G Wiman

1

1 reference

PubMed ID

20498645

21 June 2017

language of work or name

English

0 references

publication date

24 May 2010

1 reference

21 June 2017

1 reference

21 June 2017

29

1 reference

21 June 2017

4245-4252

1 reference

21 June 2017

30

1 reference

Mutant p53 rescue and modulation of p53 redox state.

21 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

DNA damage signalling guards against activated oncogenes and tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Awakening guardian angels: drugging the p53 pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

20 years studying p53 functions in genetically engineered mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Pharmacological rescue of mutant p53 conformation and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Cytoplasmic functions of the tumour suppressor p53.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Structural basis for understanding oncogenic p53 mutations and designing rescue drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Structural biology of the tumor suppressor p53.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Modeling the therapeutic efficacy of p53 restoration in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

p53 has a direct apoptogenic role at the mitochondria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Mutant p53 drives invasion by promoting integrin recycling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

The IARC TP53 database: new online mutation analysis and recommendations to users

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Rescue of mutant p53 transcription function by ellipticine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Shaping genetic alterations in human cancer: the p53 mutation paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Restoration of p53 function leads to tumour regression in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Live or let die: the cell's response to p53

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Blinded by the Light: The Growing Complexity of p53

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Strategies for therapeutic targeting of the p53 pathway in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

Mutant p53 targeting by the low molecular weight compound STIMA-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.188

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.188

1 reference

PubMed ID

20498645

Dimensions Publication ID

21 June 2017

0 references

1 reference

PubMed ID

20498645